GSK’s Older Adult Respiratory Syncytial Virus (RSV) Vaccine Candidate Shows 94.1% Reduction in Severe RSV Disease and Overall Vaccine Efficacy of 82.6% in Pivotal Trial 

GSK plc announced positive pivotal phase III trial results for its respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above to be presented at IDWeek 2022. The vaccine candidate was highly efficacious, demonstrating overall vaccine efficacy of 82.6% (96.95% CI, 57.9–94.1, 7 of 12,466 vs. 40 of 12,494) against RSV lower respiratory tract disease (RSV-LRTD), meeting the trial’s primary endpoint...READ MORE

Derm-Biome Pharmaceuticals, Inc. Reports Positive Preclinical Data in Melanoma and Squamous Cell Carcinoma, Initiates a Program Aimed at Advancing Topical Therapies for Skin Cancer to the Clinic

Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin health and healthy aging, has initiated a program aimed at advancing its topical treatments for precancerous skin conditions such as actinic keratosis and non-melanoma skin cancers such as squamous cell carcinoma through to the clinic...READ MORE

Using Health Research to Improve Health: Michael Smith Health Research BC Announce their 2022 Convening & Collaborating (C2) and Reach Awardees

Knowledge Translation (KT) activities aim to close the gap between research and implementation by improving the use of research evidence in practice, policy and further research. Through our 2022 Convening & Collaborating (C2) and Reach funding competitions, we are supporting 31 KT research teams that are creating pathways from research evidence to impact; and helping to ensure that cutting-edge research can directly improve the health of people and communities in British Columbia and BC’s health system...READ MORE

NervGen Pharma Awarded Up To $1.5 Million US Department of Defense Funding to Evaluate NervGen’s NVG-291-R for Peripheral Nerve Injury

NervGen Pharma Corp., a clinical stage biotech company dedicated to developing innovative solutions for the repair of nervous system damage, announced it has been awarded up to US$1.5 million in US Department of Defense funding from the Military Operational Medicine Research Program (MOMRP/JPC-5) to evaluate NervGen’s NVG-291-R as a therapeutic to enable accelerated and enhanced restoration of function following peripheral nerve injury...READ MORE

Roche Launches PRAME (EPR20330) Antibody to Identify PRAME Protein Expression in Patients That may Have Melanoma

Roche announced the launch of Anti-PRAME (EPR 20330) Rabbit Monoclonal Primary Antibody to identify PRAME protein expression in tissue samples from patients with suspected melanoma Because the PRAME protein is expressed in most melanomas, the PRAME (EPR20330) Antibody* is used as an aid to differentiate between benign and malignant lesions to help improve diagnostic decisions...READ MORE

Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years old

Late-breaking positive results from a Phase 3 trial evaluating the investigational use of Dupixent (dupilumab) in children aged 1 to 11 years with active eosinophilic esophagitis (EoE) will be presented at United European Gastroenterology Week 2022. The data will be submitted to regulatory authorities around the world, starting with the U.S.FDA in 2023...READ MORE

VCHRI Strategic Plan 2022-2027

Research has a profound impact on patient care and population health, and leads to a greater understanding of diseases, life-saving treatments and preventative strategies for a range of health conditions and disorders. Research discoveries and innovations also contribute to the economy through the commercialization of novel technologies and therapies...READ MORE

Evonik and Phathom Pharmaceuticals Partner to Produce Novel Acid-Blocker Vonoprazan

Evonik has entered into a long-term supply agreement with Phathom Pharmaceuticals, a U.S. biopharmaceutical company focused on developing and commercializing new treatments for gastric acid-related diseases. Through the agreement Evonik will produce large-scale volumes of vonoprazan at its FDA-inspected manufacturing sites in Tippecanoe, Indiana, USA and Dossenheim, Germany...READ MORE

Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines

Merck, known as MSD outside the United States and Canada, has been named to Fortune’s 2022 Change the World list. The annual list recognizes companies that have had a positive social impact through activities that are part of their core business strategy. Merck was selected for its work expanding global access to the company’s HPV vaccines...READ MORE

Asahi Kasei Pharma to Sponsor Research for Drug Discovery Research and Technology: Open Innovation 2023

Asahi Kasei Pharma, subsidiary of diversified Japanese multinational company Asahi Kasei, is publicly calling for new proposals for drug development research as part of its efforts for open innovation to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes and enterprises around the world. The application period begins at 5:00 a.m. GMT on January 5, 2023 and ends at 8:00 a.m. GMT on February 28, 2023...READ MORE

Trade Accelerator Program: Women-Led Cohort

Participate in the Women-led Cohort of the Trade Accelerator Program (TAP). TAP is a 5-day program designed to help SMEs TAP into their full export potential. It has a proven track record helping participants get results. With new trade agreements, a competitive Canadian dollar, and new business opportunities, now is the ideal time to extend your company’s reach through international expansion of goods and services...READ MORE

Call for Applications: 9th Annual Canada-Chicago Mentoring Program (C2MP) 

The Consulate General of Canada in Chicago is partnering once again with the MATTER healthtech incubator for the 9th edition of the Canada-Chicago Mentoring Program. This year, there is space for FIVE innovative Canadian life sciences companies who will benefit from virtual and in-person mentoring in Chicago to foster business acceleration in the U.S. healthcare market...READ MORE

Undergraduate Co-op Student – R&D Antibody Discovery – Antigen Biochemistry 

At Amgen, our shared mission—to serve patients—drives all that we do. It is key to our becoming one of the world’s leading biotechnology companies, reaching over 10 million patients worldwide. Through this program, you will acquire the valuable hands-on skills and foundational experience to become the professional you are meant to be in your chosen field.

During this co-op program, you will explore nanoparticles as means to present target membrane proteins in native form for antibody screening. You will learn several laboratory techniques, such as protein expression and purification, chromatography, cell culture and cell sorting. You will work closely with a supervisor and other scientists to advance antigen formulations that facilitate the discovery of antibodies against challenging protein targets to help fight serious diseases.

LEARN MORE

Quality Systems Specialist 

Provide Quality system support for client-funded and internal projects. Be the site Trainer to provide onboarding and refresher GMP training. Support site internal project(s) and temporary assignment(s) as assigned by Quality Management.

Develop, maintain and update applicable Quality related SOPs to assure the procedures are compliant with GMP, EHSS and company requirements.

Assure all data and records are accurate, documented and maintained effectively and in compliance with Good Documentation Practice (GDP) and data integrity requirements.

Support/ review Deviation/ Non-conformance/ Change Controls and CAPAs to assure the actions and documentation are appropriate and completed in an accurate, adequate and timely manner. 

LEARN MORE

Manager, Partnerships and Memberships 

The Manager, Partnerships & Memberships manages the planning and implementation of the principal sponsors, partners & members and retention strategies, including researching sponsors, partners & membership needs and opportunities, and securing contracts. They will also manage general services and communications to existing sponsors, partners & members to keep LSBC top of mind. The role will also oversee the management of the organization’s public job board.

To fill this position, we are looking for an energetic and positive individual that is efficient, great with details and solutions-oriented, and who enjoys working in a fast-paced environment. 

LEARN MORE

Gene Bio Medical is a one-stop comprehensive in vitro diagnostic biotechnology R&D manufacturing company based in Richmond, BC, Canada. They have independent laboratories in Canada, several medical device production lines, 100+ production technical specialists, 60+ sales associates, and a sales network all over North America.

Visit Website

3DQue produces Quinly, the automation suite that makes 3D printers smart enough to run themselves. By removing up to 99% of labour, manufacturers, machine shops and retailers can cost-effectively mass produce commercial and industrial finished goods. Quinly allows companies to bring production home so they get to market 6-9 months faster, secure their supply chain, and respond in real-time market changes quickly and easily.

Visit Website